REDHILL BIOPHARMA LTD-SP ADR (RDHL)       0.9891  +0.06 (+6.3%)

0.9891  +0.06 (+6.3%)

US7574681034 - ADR - After market: 0.988 0 (-0.11%)

REDHILL BIOPHARMA LTD-SP ADR0.9891

NASDAQ:RDHL (8/10/2022, 7:09:17 PM)+0.06 (+6.3%)

After market: 0.988 0 (-0.11%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 06-23 2022-06-23/bmo Earnings (Next) 08-25 2022-08-25/bmo
Ins Owners N/A Inst Owners 5.41%
Market Cap 52.68M Shares 53.26M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 84
IPO 02-01 2011-02-01

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RDHL Daily chart

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm is focused on the commercialization in the United States (U.S.) of the GI-related products, Movantik (naloxegol),Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). A part form Company's pipeline consists of six therapeutic candidates RHB-204 dedicated to Nontuberculous mycobacterial (NTM) treatment, RHB-104 dedicated to Crohn's disease, RHB-102 antiemetic drug ondansetron, in development for multiple gastrointestinal indications, RHB-106 an oral capsule formulation for bowel preparation, Opaganib an inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities and RHB-107 inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.

Company Info

REDHILL BIOPHARMA LTD-SP ADR

21 Ha'arba'a St.

TEL AVIV-YAFO 64739

P: 97235413131.0

CEO: Dror Ben-Asher

Employees: 201

Website: https://www.redhillbio.com/

News

News Imagea month ago - RedHill Biopharma Ltd.RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences

Talicia® - World Gastro 2022 congress (August 17-18): RedHill invited to give prestigious oral presentation of important data detailing high eradication rates...

News Image2 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time for the last breakdown of the biggest pre-market stock movers of the week and we look at what's happening Friday morning!

News Image2 months ago - RedHill Biopharma Ltd.RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented...

News Image2 months ago - RedHill Biopharma Ltd.RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report...

News Image3 months ago - RedHill Biopharma Ltd.RedHill Presents New Talicia® Data Analyses at DDW 2022

Talicia's efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population...

RDHL Twits

Here you can normally see the latest stock twits on RDHL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example